RSV Incidence Peaking In Pediatric Population, Vaccine Prevents Severe Disease
Respiratory syncytial virus is the leading cause of hospitalization among U.S. infants. A vaccine, nirsevimab, can reduce the ...
Hosted on MSN3h
Which Respiratory Virus Do I Have?
So, which respiratory virus invaded your cells? Several types of viruses could be the culprit: respiratory syncytial virus ...
What is RSV? How to spot symptoms for the respiratory illness this winter
Respiratory syncytial virus, or RSV, is a common virus that infects the nose, throat and lungs, according to the U.S. Centers ...
infectiousdiseaseadvisor.com6h
RSVPreF Vaccine Is Safe, Effective in Adults Aged 18 to 59 at Severe Risk for RSV
The RSVPreF vaccine is safe and demonstrates immunobridging to efficacy among adults aged 18 to 59 who are at high risk for ...
rheumatologyadvisor7h
RSVpreF Vaccine Effective in Preventing Severe RSV in Older Adults
RSVpreF vaccination is effective against RSV-related lower respiratory tract disease among adults aged 60 years or older.
McKnight's Long-Term Care News20h
Study: RSV vaccine may be more effective at protecting healthier older adults
The respiratory syncytial virus (RSV) vaccine may not protect older adults who are immunocompromised as much as their healthier peers, according to new research.
Pharmaceutical Technology3d
COVID-19 (S Protein) by Vaxart for Coronavirus Disease 2019 (COVID-19): Likelihood of Approval
COVID-19 (S Protein) is under clinical development by Vaxart and currently in Phase II for Coronavirus Disease 2019 (COVID-19).
Pharmaceutical Technology4d
ASC-60 by Sagimet Biosciences for Solid Tumor: Likelihood of Approval
ASC-60 is under clinical development by Sagimet Biosciences and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 69% phase transition success rate ...